8N10.F Biosergen AB
- Market cap
- EUR 3.35M
- P/E
- -
- P/B
- 51.10x
- ROE
- -323.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8N10.F undervalued?
Graham numberThe Graham number of Biosergen AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biosergen AB fundamental analysis
No fundamental analysis for Biosergen AB yet.
Biosergen AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biosergen AB
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Full company profileBiosergen AB financial statements
Biosergen AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -280K | -456K | 0.00 | 0.00 |
| Operating Income | -34.8M | -27.6M | -19.3M | -38.0M |
| EBITDA | -34.0M | -27.0M | -19.1M | -38.0M |
| Net Income | -34.0M | -27.0M | -19.2M | -38.0M |
| EPS | -5.20 | -3.45 | -8.17 | -1.77 |
| Balance Sheet | ||||
| Total Assets | 33.8M | 7.20M | 53.0M | 19.8M |
| Total Liabilities | 11.0M | 5.09M | 4.81M | 8.07M |
| Shareholders' Equity | 22.8M | 2.12M | 48.2M | 11.8M |
| Cash & Short-term Investments | 29.3M | 1.88M | 50.6M | 15.4M |
| Cash Flow | ||||
| Operating Cash Flow | -29.4M | -32.6M | -10.2M | -36.8M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -29.4M | -32.6M | -10.2M | -36.8M |
| Ratios | ||||
| ROE | -149.4% | -1,277.7% | -39.8% | -323.2% |
| ROA | -100.8% | -375.5% | -36.2% | -191.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Biosergen AB dividends
Biosergen AB has not paid dividends in the last 5 fiscal years.
Last stock split: 1:100 on Dec 1, 2025.
Who owns Biosergen AB
- Insiders 1.64%
- Institutions 0.18%
- Public & others 98.19%
- Shares outstanding 82.7M
- Free float 1.11M
Biosergen AB company profile
- Company name
- Biosergen AB
- Ticker
- 8N10.F
- ISIN
- SE0026821852
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- Fogdevreten 2, Solna, Sweden, 171 65
- Phone
- 45 3 13 55 707
- Website
- biosergen.net
About Biosergen AB
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Biosergen AB management
3- Ms. Tine Kold Olesen Ph.D.CEO & Member of Executive Board
- Mr. Mark BeveridgeChief Financial Officer · born 1978
- Mr. Sergey B. Zotchev Ph.D.Chief Scientific Officer and Member of Scientific Advisory Panel